Taken together, these results suggest that DFX treatment significantly affects pancreatic cancer cell viability, potentially through the modulation of FTH1 expression and alterations in proline and P5C metabolism, suggesting a promising therapeutic avenue for targeting pancreatic cancer. This evidence concerns the gene PYCR1 and pancreatic neoplasm.